EORTC KC Phase I (UK) v1.2
Research type
Research Study
Full title
Development of an EORTC Module to assess quality of life in patients with Keratinocyte Carcinoma (KC) - Phase I (UK)
IRAS ID
327448
Contact name
Romaana Mir
Contact email
Sponsor organisation
East & North Herts NHS Trust
Duration of Study in the UK
0 years, 4 months, 31 days
Research summary
The European Organisation of Research and Treatment of Cancer’s Quality of Life Group (EORTC QLG) has developed a four-phase framework that can be used to develop and validate quality of life questionnaires for individuals with cancer. These are developed as modules to supplement their existing EORTC core quality of life questionnaire, the ‘QLQ-C30’. For example, modules have previously been developed for endometrial cancer (QLQEN24), bone metastases (QLQ-BM22), and cancer-related fatigue (QLQ-FA12). The four-phase approach comprises a literature review followed by interviews with patients and clinicians (Phase 1), construction of a questionnaire (Phase 2), refinement of the questionnaire (Phase 3), and finally administration of the questionnaire to an international sample in a full validation study (Phase 4).
The present study aims to contribute to the development of a module designed to measure quality of life in patients with Keratinocyte Carcinoma. The study aims to undertake Phase 1 of the above module development process.
REC name
East of England - Essex Research Ethics Committee
REC reference
23/EE/0156
Date of REC Opinion
4 Jul 2023
REC opinion
Further Information Favourable Opinion